Role, Function and Effect of Catechol-O-Methyl Transferase In Humans And Parkinson Disease: Prof. Fabrizio Stocchi – PART 1, 2 & 3 OUT NOW!
An exclusive 3 part 1:1 interview, featuring industry leading expert; Professor Fabrizio Stocchi
- A knowledge of the COMT mechanism of action in humans and the areas of the brain involved.
- An understanding of the pharmacokinetics of levodopa and the effect of the addition of a COMT inhibitor.
1. Knowledge of the tolcapone pivotal trials and efficacy results in fluctuating Parkinson disease, entacapone pharmacokinetics and pharmacodynamics and how this COMT inhibitor compares with tolcapone regarding efficacy in fluctuators.
2. An understanding of the BIPARK I and II trials for opicapone including results of the open-label extension phase.
1. Knowledge of when to use a COMT inhibitor and an understanding of when motor and nonmotor symptoms may appear.
2. Recognition of the importance of screening tools to diagnose wearing-off symptoms.
The European Accreditation Committee in CNS (EACIC) has granted 1 CME credit to this 3 Part online 1:1 interview.
Details on ‘How to obtain CME credits’ will now be available following the release of Part 3.
This interview was supported by an independent educational grant by Bial